logo
Plus   Neg
Share
Email

Array BioPharma Says BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints

Array BioPharma Inc. (ARRY) reported positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI or encorafenib, a BRAF inhibitor, MEKTOVI or binimetinib, a MEK inhibitor, and ERBITUX or cetuximab, an anti-EGFR antibody or BRAFTOVI Triplet, in patients with BRAFV600E-mutant metastatic colorectal cancer or mCRC, following one or two prior lines of therapy.

The company stated that the trial met both primary endpoints of confirmed objective response rate or ORR, as assessed by Blinded Independent Central Review or BICR, and overall survival or OS.

The company plans to submit these results of the BEACON CRC trial for marketing approval in the second half of 2019.

The triplet combination of BRAFTOVI, MEKTOVI and ERBITUX for the treatment of patients with BRAFV600E-mutant mCRC is investigational and not approved by the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A survey has shown that while a majority of Americans want to buy a car that contributes substantially to the U.S. economy amid rising trade tensions, most of the "American-made" cars are actually produced by foreign automakers. According to Cars.com's 2019 American-Made Index, the most 'American-made' vehicle in 2019 is the Jeep Cherokee. Streaming giant Netflix Inc. (NFXL) is set to lose the right to stream "The Office," one of the most popular TV show on the service. NBC Universal announced it is taking back the popular TV show for its own streaming platform, beginning January 2021. "We're sad that NBC has decided to take The... Chinese smartphone maker Xiaomi has announced that its recently launched Mi Band 4 crossed 1 million units sales in just eight days. Xiaomi's Director of Product Management Donovan Sung tweeted this news as he thanked Mi fans for the achievement. "Sharing some great news with our global Mi Fans....
Follow RTT